CancerDrs

Breast Cancer clinical trials in New York

82 actively recruiting breast cancer trials at 41 sites across New York.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full breast cancer transparency page →

Phase 3 Recruiting Network

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in New York:
  • Northwell Health Imbert Cancer Center — Bay Shore, New York
  • NYU Langone Hospital - Brooklyn — Brooklyn, New York
  • Glens Falls Hospital — Glens Falls, New York
  • Northwell Health Cancer Institute at Huntington — Greenlawn, New York
  • Northwell Health/Center for Advanced Medicine — Lake Success, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

E-Mindfulness Approaches for Living After Breast Cancer

NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and …

Sponsor: NRG Oncology
NCT ID: NCT06748222
Sites in New York:
  • Mount Sinai Queens — Astoria, New York
  • Glens Falls Hospital — Glens Falls, New York
  • Garnet Health Medical Center — Middletown, New York
  • Mount Sinai Union Square — New York, New York
  • Mount Sinai Chelsea — New York, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06393374
Sites in New York:
  • The Blavatnik Family- Chelsea Medical Center at Mount Sinai ( Site 0135) — New York, New York
  • Icahn School of Medicine at Mount Sinai ( Site 0123) — New York, New York
  • Memorial Sloan Kettering Cancer Center ( Site 0067) — New York, New York
  • Clinical Research Alliance ( Site 0086) — Westbury, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor \[Retifanlimab\], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metasta…

Sponsor: BriaCell Therapeutics Corporation
NCT ID: NCT06072612
Sites in New York:
  • New York Cancer and Blood Specialists_North Shore Hematology Oncology Assocaites P.C. (Babylon) — Babylon, New York
  • NYU Langone's Perlmutter Cancer Center — Manhattan, New York
  • New York Cancer and Blood Specialists_North Shore Hematology Oncology Assocaites P.C.(New Hyde Park) — New Hyde Park, New York
  • Manhattan Hematology /Oncology Associates — New York, New York
  • New York Cancer and Blood Specialists_North Shore Hematology Oncology Assocaites P.C (NY) — New York, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizuma…

Sponsor: AstraZeneca
NCT ID: NCT06103864
Sites in New York:
  • Research Site — Albany, New York
  • Research Site — New York, New York
  • Research Site — Stony Brook, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

The purpose of this study is to investigate the efficacy and safety of BGB-43395 in combination with letrozole compared with investigator's choice of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) in combination with letrozole in patients…

Sponsor: BeOne Medicines
NCT ID: NCT07492641
Sites in New York:
  • Nyu Langone Health Perlmutter Cancer Center Sunset Park — Brooklyn, New York
  • Nyu Langone Health Perlmutter Cancer Center At Nyu Langone Hospital Long Island — Mineola, New York
  • Nyu Langone Health Perlmutter Cancer Center 34Th Street — New York, New York
  • University of Rochester — Rochester, New York
  • New York Cancer and Blood Specialists — Shirley, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positive, HER2-negative (defined as IHC 0, 1+,…

Sponsor: AstraZeneca
NCT ID: NCT06380751
Sites in New York:
  • Research Site — Brooklyn, New York
  • Research Site — Mineola, New York
  • Research Site — New Hyde Park, New York
  • Research Site — New York, New York
  • Research Site — New York, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutati…

Sponsor: Relay Therapeutics, Inc.
NCT ID: NCT06982521
Sites in New York:
  • Laura and Isaac Perlmutter Cancer Center at NYU Langone Health — New York, New York
  • Icahn School of Medicine at Mount Sinai — New York, New York
  • Columbia University Irving Medical Center — New York, New York
  • Memorial Sloan-Kettering Cancer Center — New York, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the treatment of participants with metasta…

Sponsor: Jazz Pharmaceuticals
NCT ID: NCT06435429
Sites in New York:
  • Memorial Sloan Kettering — Long Island City, New York
  • Perlmutter Cancer Center 160 E 34th St — New York, New York
  • The Mount Sinai Hospital — New York, New York
  • Columbia University Medical Center 161 Fort Washington — New York, New York
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-pa…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT06926868
Sites in New York:
  • Local Institution - 0312 — New York, New York
  • Memorial Sloan Kettering Cancer Center — New York, New York
  • Local Institution - 1037 — Syracuse, New York
  • Clinical Research Alliance — Westbury, New York
  • White Plains Hospital — White Plains, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy

The purpose of this research study is to learn more about the effects of using proton radiation therapy delivered over a shorter course of treatment (3 weeks) compared with a longer, standard course of treatment (5 weeks) for women with br…

Sponsor: Proton Collaborative Group
NCT ID: NCT05856773
Sites in New York:
  • New York Proton Center — New York, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer

The purpose of this study to test whether a comprehensive program may help the lymph fluid to drain out of the arm and prevent lymphedema in participants with breast cancer.

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06144164
Sites in New York:
  • Memorial Sloan Kettering Commack (Limited Protocol Activities) — Commack, New York
  • Memorial Sloan Kettering Westchester (Limited Protocol Activities) — Harrison, New York
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities) — New York, New York
  • Memorial Sloan Kettering Nassau (Limited Protocol Activities) — Uniondale, New York
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

The purpose of this study is to assess the efficacy and safety of RO7771950 in combination with trastuzumab and capecitabine, compared to tucatinib in combination with trastuzumab and capecitabine.

Sponsor: Hoffmann-La Roche
NCT ID: NCT07413939
Sites in New York:
  • New York Oncology Hematology, P.C. — Albany, New York
  • New York Cancer and Blood Specialists — Shirley, New York
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

ATEMPT 2.0: Adjuvant T-DM1 vs TH

This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of …

Sponsor: Dana-Farber Cancer Institute
NCT ID: NCT04893109
Sites in New York:
  • New York University Langone Hospital -Brooklyn — Brooklyn, New York
  • New York University Langone Hospital - Long Island — Mineola, New York
  • New York University Langone Health — New York, New York
  • Northwell University — New York, New York
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators o…

Sponsor: QuantumLeap Healthcare Collaborative
NCT ID: NCT01042379
Sites in New York:
  • Roswell Park Cancer Institute — Buffalo, New York
  • Laura and Isaac Perlmutter Cancer Center / NYU Langone Health — New York, New York
  • Columbia University Medical Center — New York, New York
  • University of Rochester Wilmot Cancer Institute — Rochester, New York
  • Montefiore Medical Center — The Bronx, New York
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) …

Sponsor: Puma Biotechnology, Inc.
NCT ID: NCT06369285
Sites in New York:
  • University of Rochester Medical Center — Rochester, New York
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

This study will include two groups of patients: Cohort 1 and Cohort 2. Cohort 1: will help researchers learn how a medicine called imlunestrant (LY3484356) affects a specific type of breast cancer. Some patients will take both imlunestrant…

Sponsor: Eli Lilly and Company
NCT ID: NCT07287098
Sites in New York:
  • Memorial Sloan Kettering Cancer Center — New York, New York
  • Wilmot Cancer Institute — Rochester, New York
  • New York Cancer and Blood Specialists — Shirley, New York
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…

Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in New York:
  • Columbia University Medical Center — New York, New York
  • Memorial Sloan Kettering — New York, New York
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

This phase II trial studies how well nab-paclitaxel, durvalumab, and tremelimumab with or without personalized synthetic long peptide vaccine (neoantigen vaccine) works in treating patients with triple negative breast cancer that has sprea…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03606967
Sites in New York:
  • NYP/Weill Cornell Medical Center — New York, New York
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive primary ce…

Sponsor: Fore Biotherapeutics
NCT ID: NCT05503797
Sites in New York:
  • Columbia University Irving Medical Center — New York, New York
  • Memorial Sloan Kettering Cancer Center — New York, New York
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

The Substudy Protocol ASPEN-09-03 is a Phase 2, single-arm, multicenter study evaluating the efficacy, safety, and tolerability of evorpacept in combination with trastuzumab and chemotherapy in participants with HER2-positive metastatic br…

Sponsor: ALX Oncology Inc.
NCT ID: NCT07007559
Sites in New York:
  • Memorial Sloan Kettering Cancer Center — New York, New York
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Incyclix Bio (Incyclix) is developing INX-315 as an oral, small molecule inhibitor of cyclin dependent kinase 2 (CDK2) for the treatment of human cancers. This first-in-human study is designed to evaluate the safety, tolerability, pharmaco…

Sponsor: Incyclix Bio
NCT ID: NCT05735080
Sites in New York:
  • Roswell Park Cancer Institute — Buffalo, New York
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

The purpose of this study is to test the safety and effectiveness of the sequence of two investigational drugs (trastuzumab deruxtecan followed by datopotamab deruxtecan, or datopotamab deruxtecan followed by trastuzumab deruxtecan) to lea…

Sponsor: Ana C Garrido-Castro, MD
NCT ID: NCT06533826
Sites in New York:
  • Montefiore Einstein Comprehensive Cancer Center — The Bronx, New York
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of ATX-295…

Sponsor: Accent Therapeutics
NCT ID: NCT06799065
Sites in New York:
  • NYU Longone Health (Long Island) — Long Island City, New York
  • NYU Longone Health (Manhattan) — Manhattan, New York
View on ClinicalTrials.gov →

Showing 25 of 82 trials with sites in New York. See all breast cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-01